Gilead Sciences Inc. will have to pay Merck & Co. Inc. $200 million for infringing Merck’s patent on Gilead’s blockbuster hepatitis C medications.
Although large in absolute terms, the award represents only a fraction of the damages Merck and collaboration partner Ionis Pharmaceuticals Inc. had sought to recover. Merck was asking for a 10 percent royalty on Gilead’s Sovaldi and Harvoni medications, which had rung up sales of $20 billion as of Dec. 31.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
